Do New Advances in Heart Failure Treatment Change Patient Management?

Heart failure treatments have seen major progress in recent years. Recent research confirms that drugs such as SGLT2 inhibitors, initially used for diabetes, now reduce hospitalizations and improve the quality of life for people suffering from heart failure, regardless of heart function level. These medications work by promoting the elimination of sugar and salt through urine, while also directly protecting the heart muscle and reducing inflammation.

Another significant innovation involves non-steroidal mineralocorticoid receptor antagonists. These treatments, such as finerenone, reduce the risk of death and disease progression in patients whose hearts still pump adequately but who exhibit symptoms. They complement SGLT2 inhibitors to form a solid foundation of care, especially for those whose heart failure is linked to obesity or diabetes.

In cases of hospitalization for acute heart failure, strategies have evolved. Doctors now initiate disease-modifying treatments upon admission, rather than focusing solely on eliminating excess fluids. Studies show that early initiation of medications like dapagliflozin or empagliflozin speeds up recovery and reduces relapses. Rapid adjustment of diuretics, guided by simple urine tests, also allows for better management of fluid overload.

Medical devices are playing an increasing role. Catheter-based repair of mitral and tricuspid valve leaks significantly improves symptoms and survival, particularly in patients too frail for traditional surgery. Additionally, remote monitoring of pulmonary artery pressure via implantable sensors helps prevent relapses by enabling early therapeutic adjustments.

Finally, older medications, such as digitalis, are regaining a place in recommendations for severe forms of heart failure, in addition to modern treatments. Despite these advances, their application in daily practice remains uneven, highlighting the importance of better training and rigorous patient follow-up.

These developments are transforming the management of heart failure, offering more personalized and effective solutions for a disease that affects millions of people.

Credits

Source Study

DOI: https://doi.org/10.1007/s10741-026-10609-3

Title: Heart failure evidence update 2026

Journal: Heart Failure Reviews

Publisher: Springer Science and Business Media LLC

Authors: Sotiria Liori; Chris J. Kapelios; Gianluigi Savarese; Gerasimos Filippatos